Affordable Access

Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.

Authors
  • Boz, Cavit
  • Ozmenoglu, Mehmet
  • Velioglu, Sibel
  • Kilinc, Kagan
  • Orem, Asim
  • Alioglu, Zekeriya
  • Altunayoglu, Vildan
Type
Published Article
Journal
Clinical Neurology and Neurosurgery
Publisher
Elsevier
Publication Date
Feb 01, 2006
Volume
108
Issue
2
Pages
124–128
Identifiers
PMID: 16412833
Source
Medline
License
Unknown

Abstract

Our result shows that RRMS patients have an impaired MMP-9 and TIMP-1 balance, and that 6 months of IFNbeta therapy is beneficial in restoring this balance.

Report this publication

Statistics

Seen <100 times